Index RUT
P/E 19.82
EPS (ttm) 1.39
Insider Own 3.03%
Shs Outstand 46.48M
Perf Week -2.09%
Market Cap 1.28B
Forward P/E 7.70
EPS next Y 3.58
Insider Trans -8.89%
Shs Float 45.14M
Perf Month -7.04%
Income 70.47M
PEG 2.04
EPS next Q 0.68
Inst Own 107.90%
Short Float 14.23%
Perf Quarter -3.19%
Sales 681.75M
P/S 1.88
EPS this Y -1.29%
Inst Trans 2.33%
Short Ratio 8.88
Perf Half Y -16.49%
Book/sh 19.18
P/B 1.44
EPS next Y 29.22%
ROA 4.54%
Short Interest 6.43M
Perf Year -30.34%
Cash/sh 7.00
P/C 3.94
EPS next 5Y 9.70%
ROE 8.49%
52W Range 25.33 - 40.73
Perf YTD -18.20%
Dividend Est. -
P/FCF 7.42
EPS past 5Y -
ROI 4.84%
52W High -32.24%
Beta 0.88
Dividend TTM -
Quick Ratio 4.78
Sales past 5Y 15.46%
Gross Margin 64.74%
52W Low 8.96%
ATR (14) 1.09
Dividend Ex-Date -
Current Ratio 5.81
EPS Y/Y TTM 780.50%
Oper. Margin 13.70%
RSI (14) 41.36
Volatility 3.74% 3.64%
Employees 712
Debt/Eq 0.65
Sales Y/Y TTM 1.88%
Profit Margin 10.34%
Recom 1.22
Target Price 43.56
Option/Short Yes / Yes
LT Debt/Eq 0.63
EPS Q/Q 145.11%
Payout 0.00%
Rel Volume 0.81
Prev Close 28.38
Sales Surprise 1.09%
EPS Surprise -0.02%
Sales Q/Q 4.23%
Earnings May 07 AMC
Avg Volume 723.82K
Price 27.60
SMA20 -5.15%
SMA50 -3.27%
SMA200 -7.32%
Trades
Volume 204,993
Change -2.75%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-07-24 Resumed
JP Morgan
Overweight
$80 → $45
Dec-20-23 Initiated
Raymond James
Outperform
$42
Aug-03-23 Upgrade
TD Cowen
Market Perform → Outperform
$50
Jan-31-23 Resumed
Wedbush
Outperform
$88 → $60
Oct-21-22 Resumed
Jefferies
Buy
$66
Jan-03-22 Resumed
JP Morgan
Overweight
$75 → $83
Jul-26-21 Upgrade
JP Morgan
Neutral → Overweight
$75
Apr-21-21 Resumed
JP Morgan
Neutral
$70
Apr-09-21 Initiated
Berenberg
Buy
$93
Apr-07-21 Resumed
RBC Capital Mkts
Outperform
$86
Feb-11-21 Downgrade
Northland Capital
Outperform → Market Perform
$72 → $75
Jan-21-21 Downgrade
SVB Leerink
Outperform → Mkt Perform
$75
Sep-21-20 Upgrade
Northland Capital
Market Perform → Outperform
$58 → $67
Jul-06-20 Reiterated
Needham
Buy
$52 → $64
May-27-20 Initiated
Guggenheim
Neutral
Apr-07-20 Initiated
Northland Capital
Outperform
$50
Mar-20-20 Upgrade
SVB Leerink
Mkt Perform → Outperform
$44
Feb-24-20 Reiterated
H.C. Wainwright
Buy
$60 → $63
Jan-24-20 Initiated
SunTrust
Buy
Jan-23-20 Initiated
SunTrust
Buy
Show Previous Ratings
Jun-14-24 02:41AM
Jun-06-24 11:31AM
May-30-24 08:00AM
May-10-24 07:00AM
May-08-24 04:05PM
11:35AM
Loading…
11:35AM
09:33AM
03:47AM
May-07-24 09:01PM
06:03PM
05:30PM
04:13PM
(Associated Press Finance)
04:00PM
08:00AM
Apr-30-24 08:00AM
11:33AM
Loading…
Apr-04-24 11:33AM
Apr-02-24 08:00AM
Mar-14-24 08:23AM
Mar-13-24 07:00AM
Mar-08-24 11:55PM
Mar-06-24 08:00AM
Mar-04-24 08:28PM
Mar-01-24 08:38AM
06:05AM
12:28AM
(Thomson Reuters StreetEvents)
Feb-29-24 10:00AM
09:15AM
08:32AM
08:26AM
(Associated Press Finance)
08:00AM
08:00AM
Loading…
Feb-22-24 08:00AM
Feb-15-24 08:36AM
Feb-07-24 08:00AM
Feb-01-24 10:45AM
Jan-05-24 12:21PM
Jan-04-24 05:00PM
Jan-03-24 08:00AM
Dec-21-23 07:30AM
Dec-06-23 11:13AM
Nov-13-23 10:10AM
Nov-10-23 07:30AM
Nov-07-23 08:00AM
Nov-04-23 10:28AM
Nov-02-23 12:34PM
10:00AM
08:23AM
(Associated Press Finance)
08:00AM
Oct-26-23 08:00AM
Oct-12-23 08:00AM
Oct-10-23 08:00AM
Oct-02-23 08:00AM
Sep-27-23 12:07PM
11:50AM
Sep-26-23 04:30PM
Sep-06-23 08:00AM
Aug-03-23 10:03AM
Aug-02-23 12:45PM
08:11AM
08:00AM
Jul-28-23 02:56PM
Jul-26-23 08:00AM
Jun-21-23 08:00PM
Jun-02-23 11:31AM
May-31-23 08:00AM
May-09-23 08:00AM
May-03-23 11:42PM
(Thomson Reuters StreetEvents) -7.17%
05:25PM
03:11PM
08:11AM
08:00AM
Apr-26-23 08:00PM
08:00AM
Apr-20-23 09:20AM
08:00AM
Apr-19-23 08:00AM
Apr-12-23 08:00AM
Apr-03-23 08:00AM
Mar-30-23 11:30AM
Mar-29-23 08:00AM
Mar-27-23 08:00AM
Mar-24-23 08:50AM
Mar-22-23 08:00AM
Mar-09-23 09:17AM
Mar-08-23 08:00AM
Feb-28-23 11:39PM
(Thomson Reuters StreetEvents)
08:00AM
Feb-23-23 08:00AM
Feb-21-23 08:00AM
Jan-05-23 04:30PM
Jan-04-23 08:00AM
Dec-20-22 10:06AM
Dec-13-22 08:00AM
Nov-18-22 01:38PM
Nov-17-22 08:05AM
Nov-14-22 08:00AM
Nov-09-22 05:14AM
Nov-08-22 08:00AM
Nov-04-22 10:54AM
Nov-03-22 09:15AM
08:00AM
Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
WILLIAMS KRISTEN Chief Administrative Officer Jun 13 '24 Sale 28.38 7,452 211,488 102,912 Jun 13 06:12 PM GAUGLER DARYL Chief Operating Officer Jun 13 '24 Sale 28.38 1,000 28,380 116,040 Jun 13 06:13 PM HASTINGS PAUL J Director Jun 13 '24 Sale 28.38 880 24,974 12,724 Jun 13 06:13 PM RIKER LAUREN Senior Vice President, Finance Jun 12 '24 Sale 28.72 3,970 114,018 38,075 Jun 13 06:15 PM SLONIN JONATHAN Chief Medical Officer Jun 11 '24 Sale 28.57 5,012 143,193 44,569 Jun 13 06:15 PM PACE GARY W Director Mar 08 '24 Sale 30.60 90,000 2,754,000 22,127 Mar 08 05:33 PM PACE GARY W Director Mar 07 '24 Sale 30.81 28,257 870,598 112,127 Mar 08 05:33 PM PACE GARY W Director Mar 06 '24 Sale 29.67 1,066 31,628 140,384 Mar 08 05:33 PM WINSTON ROY Chief Medical Officer Aug 02 '23 Sale 34.88 509 17,751 52,440 Aug 04 04:47 PM Riker Lauren Bullaro Senior Vice President, Finance Jul 05 '23 Sale 38.91 643 25,019 22,687 Jul 07 08:04 PM
Index -
P/E -
EPS (ttm) -0.90
Insider Own 8.09%
Shs Outstand 44.68M
Perf Week -11.26%
Market Cap 99.22M
Forward P/E -
EPS next Y -1.06
Insider Trans 0.00%
Shs Float 41.11M
Perf Month -35.51%
Income -40.25M
PEG -
EPS next Q -0.25
Inst Own 18.98%
Short Float 10.85%
Perf Quarter -58.84%
Sales 0.61M
P/S 162.65
EPS this Y -5.11%
Inst Trans -10.88%
Short Ratio 6.17
Perf Half Y 50.93%
Book/sh 1.36
P/B 1.63
EPS next Y -8.44%
ROA -44.55%
Short Interest 4.46M
Perf Year 46.93%
Cash/sh 1.50
P/C 1.48
EPS next 5Y -
ROE -51.12%
52W Range 0.94 - 6.42
Perf YTD 49.91%
Dividend Est. -
P/FCF -
EPS past 5Y 35.42%
ROI -64.72%
52W High -65.44%
Beta 1.93
Dividend TTM -
Quick Ratio 5.91
Sales past 5Y 9.26%
Gross Margin 32.79%
52W Low 136.02%
ATR (14) 0.22
Dividend Ex-Date -
Current Ratio 5.91
EPS Y/Y TTM -1.77%
Oper. Margin -7261.15%
RSI (14) 17.08
Volatility 6.50% 7.15%
Employees 32
Debt/Eq 0.03
Sales Y/Y TTM 54.43%
Profit Margin -6598.85%
Recom 1.00
Target Price 10.50
Option/Short Yes / Yes
LT Debt/Eq 0.02
EPS Q/Q 10.78%
Payout -
Rel Volume 1.10
Prev Close 2.26
Sales Surprise 228.00%
EPS Surprise 11.47%
Sales Q/Q 146.99%
Earnings May 02 AMC
Avg Volume 722.90K
Price 2.22
SMA20 -22.10%
SMA50 -36.21%
SMA200 -10.46%
Trades
Volume 277,949
Change -1.83%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-05-22 Initiated
William Blair
Outperform
Dec-08-21 Initiated
Robert W. Baird
Outperform
$19
Aug-09-21 Resumed
Maxim Group
Buy
$30 → $20
Oct-22-20 Initiated
H.C. Wainwright
Buy
$27
Oct-08-20 Initiated
Piper Sandler
Overweight
$25
May-29-24 04:05PM
May-13-24 04:05PM
May-09-24 12:15PM
May-07-24 06:00AM
May-02-24 09:54PM
(InvestorPlace) +5.91%
-21.43%
05:45PM
Loading…
05:45PM
04:05PM
Apr-25-24 04:05PM
Apr-08-24 04:05PM
Apr-01-24 08:50AM
Mar-21-24 07:55AM
Mar-14-24 08:50AM
08:08AM
Mar-06-24 04:05PM
(GlobeNewswire) +6.58%
-9.77%
12:00PM
10:12AM
Loading…
Mar-01-24 10:12AM
Feb-29-24 07:40PM
04:07PM
04:06PM
04:05PM
Feb-26-24 08:00AM
Feb-22-24 08:00AM
Jan-17-24 10:30AM
Nov-20-23 04:05PM
Nov-02-23 04:05PM
Oct-26-23 04:05PM
Oct-23-23 08:45AM
Oct-11-23 09:35AM
Sep-26-23 04:05PM
Sep-05-23 08:00AM
04:05PM
Loading…
Aug-09-23 04:05PM
(PR Newswire) -12.39%
+8.38%
Aug-07-23 04:05PM
(PR Newswire) -8.19%
+38.85%
Jul-24-23 05:09PM
Jun-20-23 05:22PM
Jun-05-23 08:00AM
May-04-23 04:10PM
Mar-28-23 08:00AM
Mar-06-23 08:15AM
Mar-04-23 07:11AM
Mar-02-23 04:10PM
Feb-27-23 08:15AM
Feb-02-23 08:00AM
Jan-10-23 08:00AM
Nov-21-22 10:52AM
Nov-08-22 08:15AM
Nov-03-22 04:10PM
Sep-12-22 04:05PM
(PR Newswire) +10.69%
-41.12%
Sep-10-22 07:30AM
Sep-08-22 08:15AM
Sep-06-22 08:00AM
Aug-29-22 08:00AM
Aug-04-22 04:10PM
Jul-05-22 08:30AM
Jul-02-22 09:10AM
May-17-22 08:30AM
May-09-22 08:02AM
May-05-22 04:10PM
Apr-12-22 04:00PM
Apr-08-22 01:05PM
01:05PM
Mar-22-22 09:05AM
Mar-17-22 06:32AM
Mar-08-22 04:45PM
Mar-01-22 08:30AM
Feb-24-22 04:10PM
Feb-17-22 03:02PM
Jan-31-22 06:22PM
Jan-20-22 03:44PM
01:46PM
Jan-18-22 05:00PM
(PR Newswire) -10.50%
-25.90%
Jan-13-22 09:17AM
Jan-11-22 08:00AM
Jan-10-22 08:00AM
Jan-04-22 08:00AM
Dec-28-21 09:38AM
Dec-21-21 09:38AM
Dec-16-21 09:38AM
Dec-10-21 08:30AM
Dec-08-21 09:38AM
Dec-03-21 08:30AM
Nov-18-21 07:00AM
Nov-14-21 07:18AM
Nov-09-21 08:30AM
Nov-04-21 04:15PM
Oct-28-21 03:06PM
Sep-30-21 08:36PM
Sep-15-21 06:37AM
Sep-08-21 04:00PM
Sep-07-21 08:30AM
Aug-25-21 08:15AM
Aug-06-21 04:15AM
(Simply Wall St.) +11.84%
Aug-05-21 04:15PM
Aug-03-21 03:01PM
Jul-12-21 08:00AM
Jul-06-21 08:30AM
Jun-28-21 08:30AM
Jun-10-21 12:30PM
Jun-08-21 08:30AM
May-24-21 08:35AM
02:09AM
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
PACE GARY W Director Dec 19 '23 Buy 1.37 30,000 41,100 697,761 Dec 19 06:39 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite